Guselkumab treatment of psoriasis results in sustained reduction of systemic inflammatory biomarkers to week 48 in three phase III randomized controlled trials
Niamh Kearney, Miriam Zimmermann, Alianu Akawung, Brian Kirby · 2026
Read Guselkumab treatment of psoriasis results in sustained reduction of systemic inflammatory biomarkers to week 48 in three phase III randomized controlled trials by Niamh Kearney, Miriam Zimmermann, Alianu Akawung, Brian Kirby (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13425078.txt.
Description
Niamh Kearney and coauthors published a 2026 post hoc analysis of guselkumab treatment in psoriasis across three phase III trials. Earlier results from VOYAGE 1, VOYAGE 2, and ECLIPSE showed lower inflammatory markers through weeks 12 to 16. The new analysis asks whether those reductions held through week 48 and tracks measures such as the neutrophil to lymphocyte ratio.
Sustained biomarker lowering matters because systemic inflammation in psoriasis may raise the risk of major cardiac events. Readers see longer-term laboratory follow-up from randomized trial populations rather than short treatment snapshots alone. The work keeps the focus on care that lasts well past the first weeks of skin care.
Catalog record
| CREATOR | Niamh Kearney, Miriam Zimmermann, Alianu Akawung, Brian Kirby |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12811 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |